TGA provisionally approves Moderna's new bivalent Covid vaccine

The TGA has granted provisional approval to Moderna's bivalent COVID-19 vaccine, SPIKEVAX (elasomeran and davesomeran), for use as a booster dose in individuals aged 12 years and older.

The regulator said that this is the second bivalent vaccine targeting the Omicron BA.4-5 subvariants that it has been provisionally approved. It follows the provisional approval of Pfizer's COMIRNATY BIVALENT Omicron BA.4/BA.5 COVID-19 vaccine on 20 January 2023.

"The TGA carefully considered data from an ongoing Phase II/III study, which showed that the vaccine elicited a superior neutralising antibody response against the Omicron BA.4/BA.5 strain compared to the original (monovalent) SPIKEVAX vaccine," said the regulator.

"The vaccine also elicited a good neutralising antibody response against a number of other currently circulating and emerging variants."

The TGA said the potential use of this vaccine in the national COVID-19 vaccination program is still to be determined.

"The Australian Technical Advisory Group on Immunisation (ATAGI) will provide advice to the Government on these matters in coming weeks," it said.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.